Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
about
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesGenome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemiaPilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology GroupImmaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection.Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.Detection of minimal residual disease in acute leukemia by flow cytometry.The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease.Cytogenetics and molecular genetics of childhood leukemia.Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trialThe management of high-risk lymphoblastic leukaemia in children.Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.Molecular diagnostic approach to non-Hodgkin's lymphoma.Use of reporter genes for optical measurements of neoplastic disease in vivoImproved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology.The clinical path to integrated genomics in ALL.Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation.A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALLPotential clinical impact of three-dimensional visualization for fluorescent in situ hybridization image analysis.Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingEarly response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review.Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemiaMinimal residual disease surveillance in chronic lymphocytic leukemia by fluorescence-activated cell sorting.Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.Technical issues: flow cytometry and rare event analysis.Noninvasive identification of subcellular organization and nuclear morphology features associated with leukemic cells using light-scattering spectroscopyMinimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction.New markers for minimal residual disease detection in acute lymphoblastic leukemia.The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemiaAugmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.Bone marrow transplant in Ph+ ALL patients.Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.Molecular genetic events in adult acute lymphoblastic leukemia.Determination of minimal residual disease in leukaemia patients.Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.Optimal chemotherapy for leukemia: a model-based strategy for individualized treatment.
P2860
Q24685514-0AF311C6-9913-407C-AF77-D3B64B7D0C82Q26825970-A84758E7-4429-4111-8DAF-E80FED90A9D1Q26828511-846445E9-0F50-4089-9EC0-EC01BB0A9042Q28943308-38043FC4-89FF-4730-9A56-ED121379286AQ30417943-FF9B6A7C-D597-4233-B992-7CE20299825CQ30432481-3FF2DEE5-1D1C-441E-A7B1-DFA41C71A202Q33588450-6196BAE2-96F7-4833-A84B-A3ECEC28B750Q33656184-40C0F425-D21F-4F80-994F-1F8F9BE16407Q33707273-D4FA218A-604E-4F35-9FFF-896869B9BD8DQ33723609-E3E2A86F-9273-407E-81DF-35492DC2AB6BQ33820790-84DF67C5-36D9-4C52-ABDA-92D2E76E644FQ33828580-1F9954BA-7A17-4AB4-AF35-9AAE05381718Q33848509-2630CFF8-A0CD-4585-B798-AB040F136CA8Q33929829-EC23B407-16A4-4CA4-A93A-C0BC0BA0A650Q33931882-0ADC3DDB-08C2-4470-BEBD-9EE2C97CF2B1Q33936373-7625F2DD-9EF5-48A2-93E1-A8683B92F85DQ33995764-CA5DC692-3FB1-4405-B2D3-A3748F3CF015Q33997207-B3B747A8-A650-4B1E-A4AD-B82E727E15F4Q34016431-8B5D7A16-1433-4140-85DE-FF0D543AE77EQ34106773-DD303333-AF75-4577-A523-4ADE08669FCFQ34135330-DF3FA363-01B1-4C7F-9792-1A6AA52D3B2DQ34217173-AF715E21-EED5-4048-A569-23DE3E1DBC55Q34275968-271A0A21-AB30-46EF-BFA7-78CCC9505209Q34425875-6A96EC01-5211-46F3-9C33-EC7F0861666BQ34448334-028099A5-AB10-4239-A248-CAEC7432D4D7Q34449151-66B0B011-5E7A-41E1-94E9-B48BE93B4DD1Q34463414-6FEE0D92-2B7A-4340-A9E3-A677B4603502Q34532041-509474EE-D7D9-487F-8186-03D87107957EQ34670653-ED40F6DA-E813-40A2-826C-96DD7A8566E9Q34849823-E609C994-5AAF-4A3A-B713-93A6FC30154FQ34920196-06A3307D-8E07-47D2-99A0-2C74B2254067Q35067391-C2FAD67A-CD13-48E7-8B25-5B3F8508CB17Q35094049-97C56E4E-6CC1-4442-AAF4-EF1A3F94FB71Q35106033-7FBC6BE2-9702-4828-BE7E-E67CF8206E1FQ35106125-26EAF1F0-D0FA-4AA6-8B2C-0E598AA9C00EQ35134983-9CD02208-9BEC-44A7-BE6F-D77A048926D1Q35142172-E8752907-ACDD-45AE-8B51-D9DDA41A764BQ35145184-AC397B97-10AE-468A-9742-77F90AC0D16AQ35161219-118A0363-25BF-4CE5-BEA4-B15B25E2E768Q35327001-AE3C8FC1-4546-454C-B2E7-5BBA06296908
P2860
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Clinical significance of minim ...... od Leukemia Cooperative Group.
@en
Clinical significance of minim ...... od Leukemia Cooperative Group.
@nl
type
label
Clinical significance of minim ...... od Leukemia Cooperative Group.
@en
Clinical significance of minim ...... od Leukemia Cooperative Group.
@nl
prefLabel
Clinical significance of minim ...... od Leukemia Cooperative Group.
@en
Clinical significance of minim ...... od Leukemia Cooperative Group.
@nl
P2093
P1476
Clinical significance of minim ...... od Leukemia Cooperative Group.
@en
P2093
Grandchamp B
Thielemans K
Waterkeyn C
van der Werff ten Bosch J
P304
P356
10.1056/NEJM199808273390904
P407
P577
1998-08-01T00:00:00Z